{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:43:04Z","timestamp":1777160584162,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Population screening programmes must make good use of resources for the health system and users. To evaluate impacts of the type of diagnostic test in the new French cervical screening programme, an messenger ribonucleic acid (mRNA) high-risk human papillomavirus assay was compared to a deoxyribonucleic acid (DNA) high-risk human papillomavirus assay for a hypothetical cohort of women aged 25 to 65 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Perspective:<\/jats:title>\n            <jats:p>This evaluation takes the perspective of the French healthcare system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>France<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A decision tree model reflecting the French cervical screening algorithms was parametrised using French cost and population data and the Danish Horizon study. The outcomes were total costs, and number of colposcopies, HPV tests and cytology tests for the cohort. One-way and probabilistic sensitivity analyses and scenarios analyses were conducted to test the robustness of results to parameter and structural uncertainty.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Adopting an mRNA versus DNA assay as part of national cervical screening in France is estimated to save \u20ac6.5 million (95% credibility intervals \u20ac-1.3 - \u20ac13.5 million) and prevent 47,795 (95% credibility intervals 35,309 - 60,139) unnecessary colposcopies, 38,666 unnecessary HPV tests and 121,670 cytology tests over two years for a cohort of 2,168,806 million women aged 25 to 65 years. Sensitivity analyses indicated robust results across a range of inputs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The choice of high-risk human papillomavirus assay makes a significant difference to resource use and costs and is important to consider when implementing cervical screening in France. Using an mRNA versus DNA assay can result in cost savings and reductions in unnecessary testing and procedures, which in turn benefits women and the health care system.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029530","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T14:08:58Z","timestamp":1658498938000},"page":"e29530","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4983-3762","authenticated-orcid":false,"given":"Caroline A.","family":"Dombrowski","sequence":"first","affiliation":[{"name":"Aquarius Population Health, Unit 29 Tileyard Studios, London N7 9AH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgie MF","family":"Weston","sequence":"additional","affiliation":[{"name":"Aquarius Population Health, Unit 29 Tileyard Studios, London N7 9AH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pr Philippe","family":"Descamps","sequence":"additional","affiliation":[{"name":"Department of Ob-gyn, University Hospital, 4 rue Larre, Angers cedex 01. France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pr Jacques","family":"Izopet","sequence":"additional","affiliation":[{"name":"U1043; UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), CHU Toulouse, H\u00f4pital Purpan, Virology Laboratory, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth J.","family":"Adams","sequence":"additional","affiliation":[{"name":"Aquarius Population Health, Unit 29 Tileyard Studios, London N7 9AH, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Adams","sequence":"additional","affiliation":[{"name":"Aquarius Population Health, Unit 29 Tileyard Studios, London N7 9AH, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"R1-20250504","article-title":"Human papillomavirus and related diseases in France","author":"Bruni","year":"2019","journal-title":"Summary Report ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ijc.11530","article-title":"Cervical cancer control, priorities and new directions","volume":"108","author":"Monsonego","year":"2004","journal-title":"Int J Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":"Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections","volume":"100","author":"Rodr\u00edguez","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/JCM.01013-15","article-title":"Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. Tang Y-W, ed","volume":"53","author":"Iftner","year":"2015","journal-title":"J Clin Microbiol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e014626","DOI":"10.1136\/bmjopen-2016-014626","article-title":"Organised screening for cervical cancer in France: a cost-effectiveness assessment","volume":"7","author":"Barr\u00e9","year":"2017","journal-title":"BMJ Open"},{"key":"R6-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/v10120729","article-title":"Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing","volume":"10","author":"Chrysostomou","year":"2018","journal-title":"Viruses"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CEJ.0000000000000365","article-title":"Population-based organized cervical cancer screening pilot program in France","volume":"27","author":"Hamers","year":"2018","journal-title":"Eur J Cancer Prev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2018.09.004","article-title":"Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial","volume":"108","author":"Cook","year":"2018","journal-title":"J Clin Virol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2012.01.002","article-title":"Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study)","volume":"125","author":"Monsonego","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R12-20250504","first-page":"S40","article-title":"A review of the clinical performance of the Aptima HPV assay","volume":"76","author":"Haedicke","year":"2016","journal-title":"Recent Adv Mol Detect Hum Papillomavirus Cerv Cancer Screen"},{"key":"R13-20250504","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01177-18","article-title":"Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany","volume":"57","author":"Iftner","year":"2019","journal-title":"J Clin Microbiol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ijc.27636","article-title":"The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy","volume":"132","author":"Arbyn","year":"2013","journal-title":"Int J Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcv.2016.12.004","article-title":"Aptima HPV Assay versus Hybrid Capture\u00ae 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial","volume":"87","author":"Cook","year":"2017","journal-title":"J Clin Virol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ijc.25726","article-title":"Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study","volume":"129","author":"Monsonego","year":"2010","journal-title":"Int J Cancer"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/bjc.2013.22","article-title":"Comparing the performance of six human papillomavirus tests in a screening population","volume":"108","author":"Cuzick","year":"2013","journal-title":"Br J Cancer"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.01517-13","article-title":"The aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening","volume":"51","author":"Heideman","year":"2013","journal-title":"J Clin Microbiol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/ijc.31819","article-title":"HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri","volume":"144","author":"Forslund","year":"2019","journal-title":"Int J Cancer"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"e031303","DOI":"10.1136\/bmjopen-2019-031303","article-title":"Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation","volume":"10","author":"Weston","year":"2020","journal-title":"BMJ Open"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e0147326","DOI":"10.1371\/journal.pone.0147326","article-title":"Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above","volume":"11","author":"Rebolj","year":"2016","journal-title":"Plos One"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.ejca.2015.04.012","article-title":"A daunting challenge: human papillomavirus assays and cytology in primary cervical screening of women below age 30years","volume":"51","author":"Rebolj","year":"2015","journal-title":"Eur J Cancer"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial","volume":"320","author":"Ogilvie","year":"2018","journal-title":"JAMA"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"101448","DOI":"10.1016\/j.pmedr.2021.101448","article-title":"A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada","volume":"23","author":"Weston","year":"2021","journal-title":"Prev Med Rep"},{"key":"R33-20250504","first-page":"26","article-title":"Final results of the evaluation of organized screening for cervical cancer in 13 departments in France, 2010-2014.","author":"Beltzer","year":"2017","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"l240","DOI":"10.1136\/bmj.l240","article-title":"Primary cervical screening with high risk human papillomavirus testing: observational study","volume":"364","author":"Rebolj","year":"2019","journal-title":"BMJ"},{"key":"R35-20250504","first-page":"424","article-title":"Evolution of the vaccination coverage of the papillomavirus vaccine in France - 2008-2018","author":"Fonteneau","year":"2019","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2013.12.005","article-title":"The Australian experience with the human papillomavirus vaccine","volume":"36","author":"Garland","year":"2014","journal-title":"Clin Ther"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1359105309351249","article-title":"The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV+ women","volume":"15","author":"Daley","year":"2010","journal-title":"J Health Psychol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/LGT.0b013e31829c97d8","article-title":"The unintended consequences of cervical screening: distress in women undergoing cytologic surveillance","volume":"18","author":"Sharp","year":"2014","journal-title":"J Low Genit Tract Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:19:51Z","timestamp":1746332391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":30,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029530","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}